MoonLake Immunotherapeutics
MLTX
$16.77
$0.040.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.21M | 10.80M | 10.94M | 11.03M | 9.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.22M | 71.43M | 60.70M | 47.49M | 49.58M |
| Operating Income | -65.22M | -71.43M | -60.70M | -47.49M | -49.58M |
| Income Before Tax | -62.77M | -70.58M | -55.96M | -40.41M | -46.35M |
| Income Tax Expenses | 248.00K | 115.00K | 95.00K | 153.00K | 41.00K |
| Earnings from Continuing Operations | -63.02M | -70.69M | -56.05M | -40.56M | -46.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 591.00K | 965.00K | 831.00K | 615.00K | 790.00K |
| Net Income | -62.43M | -69.73M | -55.22M | -39.94M | -45.61M |
| EBIT | -65.22M | -71.43M | -60.70M | -47.49M | -49.58M |
| EBITDA | -64.47M | -70.69M | -59.96M | -47.11M | -49.22M |
| EPS Basic | -0.92 | -1.10 | -0.87 | -0.63 | -0.72 |
| Normalized Basic EPS | -0.57 | -0.68 | -0.54 | -0.39 | -0.45 |
| EPS Diluted | -0.92 | -1.10 | -0.87 | -0.63 | -0.72 |
| Normalized Diluted EPS | -0.57 | -0.68 | -0.54 | -0.39 | -0.45 |
| Average Basic Shares Outstanding | 67.97M | 63.37M | 63.28M | 63.23M | 63.07M |
| Average Diluted Shares Outstanding | 67.97M | 63.37M | 63.28M | 63.23M | 63.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |